# Survodutide

> GLP-1/glucagon dual agonist in late-stage obesity trials.

Source: https://peptides.cafe/peptide/survodutide
Category: Metabolic · Incretin
Tag: Weight loss

## Mechanism
A dual agonist of the GLP-1 and glucagon receptors. The glucagon arm adds an energy-expenditure component on top of GLP-1's appetite and glycemic effects.

## Research areas
- Chronic weight management
- MASH / fatty liver disease
- Type 2 diabetes

## Common research protocols
- Weekly subcutaneous clinical research: Phase 3 trials use weekly subcutaneous dose escalation.

## Study summaries
- "Survodutide for obesity (Phase 2)" — The Lancet Diabetes & Endocrinology (2024): Up to ~19% mean weight loss at 46 weeks.

## Considerations
- Investigational; not yet FDA-approved.
- GI side effects are dose-limiting.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.